C18orf32

Across TCGA pan-cancer cohorts, C18orf32 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C18orf32 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher C18orf32 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C18orf32 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC and UCEC are the cancer types where C18orf32 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.147	0.769	<.001	30	view →
UCEC	DFS	Median	All	1.000	0.629	.018	26	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

C18orf32–HNSC (OS)

Open the HNSC breakdown →